Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Dec;10(6):475-480.
doi: 10.2217/clp.15.37. Epub 2015 Nov 23.

Effects of Armolipid Plus on small dense LDL particles in a sample of patients affected by familial combined hyperlipidemia

Marco Gentile  1 , Ilenia Calcaterra  1 , Alfonso Strazzullo  1 , Carmen Pagano  1 , Delia Pacioni  1 , Enza Speranza  1 , Paolo Rubba  1 , Gennaro Marotta  1
Affiliations

Effects of Armolipid Plus on small dense LDL particles in a sample of patients affected by familial combined hyperlipidemia

Marco Gentile et al. Clin Lipidol. 2015 Dec.

Abstract

Aim: The aim of this study was to test small dense LDL changes with Armolipid Plus treatment in patients with familial combined hyperlipidemia (FCHL).

Methods: After 4 weeks, 30 patients with FCHL were included in an 8-week, randomized, double-blind study and were taking, in addition to the standard diet, either placebo or Armolipid Plus.

Results: The placebo group showed no statistically significant differences in the studied parameters; instead, in the Armolipid Plus group, statistically significant reduction differences were detected in BMI (p = 0.010), LDL score (p = 0.035) and an increase in mean LDL particle diameter (p = 0.040).

Conclusion: The combination of a standard diet with Armolipid Plus is able to reduce LDL score and increase LDL particle diameter in a group of FCHL after 8 weeks of treatment.

Keywords: Armolipid Plus; familial combined hyperlipidemia; small dense LDL.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Modifications of LDL score
(A) Armolipid Plus group (n = 14) and (B) placebo group (n = 15). Values are expressed as mean ± standard deviation.
Figure 2
Figure 2. Modifications of mean LDL size
(A) Armolipid Plus group (n = 14) and (B) placebo group (n = 15).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. van Greevenbroek MM, Stalenhoef AF, de Graaf J, Brouwers MC. Familial combined hyperlipidemia: from molecular insights to tailored therapy. Curr. Opin. Lipidol. 2014;25:176–182. - PubMed
    1. Hopkins PN, Heiss G, Ellison RC, et al. Coronary artery disease risk in familial combined hyperlipidemia and familial hypertriglyceridemia: a case–control comparison from the National Heart, Lung, and Blood Institute Family Heart Study. Circulation. 2003;108:519–523. - PubMed
    1. Pauciullo P, Gentile M, Marotta G, et al. Small dense low-density lipoprotein in familial combined hyperlipidemia: independent of metabolic syndrome and related to history of cardiovascular events. Atherosclerosis. 2009;203:320–324. [This paper reported association between LDL score and familial combined hyperlipidemia.] - PubMed
    1. Mykkanen L, Kuusisto J, Haffner SM, Laakso M, Austin MA. LDL size and risk of coronary heart disease in elderly men and women. Arterioscler. Thromb. Vasc. Biol. 1999;19:2742–2748. - PubMed
    1. Austin MA, Breslow JL, Hennekens CH, Buring JE, Willett WC, Krauss RM. Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA. 1988;260:1917–1921. - PubMed

LinkOut - more resources